Biogen

News

CMS decision on Aduhelm is in, and it's bad news for Biogen

The US Centres for Medicare and Medicaid Services (CMS) has firmed up its draft decision to limit reimbursement of Biogen's Alzheimer's disease therapy Aduhelm to a few thousand patients en

News

New blow for ALS pipeline as Biogen and Ionis candidate fail...

Less than six months after the late-stage failure of tofersen, Biogen and Ionis have suffered further disappointment in the amyotrophic lateral sclerosis (ALS) pipeline after BIIB078 (IONIS-C9Rx) f

News

Ex-Biogen R&D head Sandrock takes the top job at Voyager

Voyager Therapeutics has lost little time in elevating Al Sandrock to the chief executive position, with the appointment coming just a few weeks after he joined the biotech's board.

News

Biogen finally publishes its phase 3 Aduhelm data

After months of debate about the validity of its phase 3 clinical trials for Alzheimer's therapy Aduhelm, Biogen has published the results in a peer-review journal, allowing physicians to l

News

Eisai hands off responsibility for Aduhelm to Biogen

Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer's therapy Aduhelm, handing over full responsibility to its US counterpart.

News

Pharma group seeks digital measure standards for Alzheimer's

A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the develo

CMS decision on Aduhelm is in, and it's bad news for Biogen

New blow for ALS pipeline as Biogen and Ionis candidate fail...

Ex-Biogen R&D head Sandrock takes the top job at Voyager

Biogen finally publishes its phase 3 Aduhelm data

Eisai hands off responsibility for Aduhelm to Biogen

Pharma group seeks digital measure standards for Alzheimer's

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

Biogen

Editor's Picks